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An acidic residue in transmembrane segment (TMS) 10 is important for recognition of bivalent cationic
substrates by the QacA multidrug transporter. Remarkably, an acidic residue in TMS 12 compensated for the
absence of such a residue in TMS 10, suggesting that TMS 12 is a component of the bivalent cation-binding
region.
The Staphylococcus aureus multidrug transport protein
QacA is a member of the drug:H antiporter (DHA) 2 family
of the major facilitator superfamily and is composed of 514
amino acid residues organized into 14 -helical transmem-
brane segments (TMS) (Fig. 1) (4). The multidrug recognition
profile of the QacA transporter is distinct from that of the
closely related QacB protein, in that QacA confers high-level
resistance to both monovalent and bivalent cationic antimicro-
bials, whereas QacB provides poor resistance to bivalent cat-
ions (9). Previous studies have shown that of the six amino acid
differences between QacA and QacB, only one, the incorpo-
ration of an aspartic acid residue at position 323 (D323) in
TMS 10 of QacA in place of an alanine at this position in
QacB, is required to extend the substrate recognition profile of
QacA to include bivalent molecules (Fig. 1) (9). In the absence
of D323, an acidic residue in one of two other positions in TMS
10, 320 or 322, can also promote bivalent substrate recognition
(9, 11). These positions are thought to line the binding site for
bivalent cationic drugs in QacA, situating the acidic residues
such that they can participate in electrostatic interactions with
bivalent substrates (7, 9, 11).
Similar to QacA, electrostatic interactions are thought to be
highly important in the binding of cationic drugs by other
multidrug-binding proteins. For example, crystal structures of
the QacA regulatory protein, QacR, which binds a range of
monovalent and bivalent cationic antimicrobial compounds
similar to that bound by QacA, show that the positive charges
carried by these compounds are typically neutralized by one of
five glutamic acid residues which line the drug-binding pocket
in QacR (8, 10). Additionally, neutralization of E26 in TMS 1
of the Escherichia coli DHA1 family multidrug transporter
MdfA disrupts the capacity of MdfA to recognize a large num-
ber of cationic substrates (2, 5), and the neutralization of either
one of two acidic residues in the lactococcal DHA1 family
multidrug transport protein LmrP abolishes the transport of
bivalent, but not monovalent, cationic substrates by this pro-
tein (6).
A study investigating the genetic diversity and distribution of
genes encoding QacA/B transport proteins within clinical S.
aureus strains from Japan identified three variants which en-
coded proteins containing no acidic residues in TMS 10 but a
glutamic acid residue in place of a glycine at amino acid posi-
tion 377 (G377E) in TMS 12 (Fig. 1) (3). Due to the unfavor-
able energetic cost, charged residues are unlikely to be buried
within the membrane without conferring a selective advantage
on the protein. Therefore, the maintenance of the G377E
alteration within three distinct QacA/B variants was intriguing.
To investigate whether the properties of the amino acid resi-
due at position 377 could influence the substrate specificity of
QacA, the phenotypic effects of acidic and neutral substitu-
tions at this position were determined in the presence of D323
and after its neutralization by cysteine substitution.
Site-directed mutagenesis using the Stratagene QuikChange
method was used to incorporate glutamic acid, aspartic acid,
glutamine, or cysteine substitutions for G377 in both wild-type
QacA and D323C QacA mutant templates (11). Each of the
eight mutants was expressed at close to wild-type levels in E.
coli DH5 cells, as determined by Western analysis with a
QacA-specific antiserum (Table 1). The ability of the mutants
to confer resistance to six QacA substrates, selected as repre-
sentatives from different chemical classes and including both
monovalent and bivalent compounds, was examined using MIC
analysis. As shown previously (11), the QacA D323C mutant
conferred only background levels of resistance to each of the
bivalent drugs tested while maintaining wild-type or greater
levels of resistance to monovalent substrates (Table 1). Al-
though the rhodamine 6G resistance levels conferred by the
D323C-G377C/D/E/Q QacA mutants were lower than those
conferred by the D323C mutant, these mutant proteins re-
tained a high overall capacity to confer resistance to monova-
lent cationic substrates (Table 1). Furthermore, neither of the
two neutral amino acid substitutions for G377 in the D323C
QacA background (viz., D323C-G377C and D323C-G377Q)
caused a significant increase in the overall level of bivalent
drug resistance observed, although the level of resistance to
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dequalinium conferred by these mutants was slightly above
background (Table 1). In contrast, the G377E and particularly
the G377D amino acid substitutions restored significant levels
of dequalinium and chlorhexidine resistance and low levels of
pentamidine resistance to strains with the D323C mutant pro-
tein (Table 1). Therefore, an acidic residue at amino acid
position 377 in TMS 12 can functionally compensate for the
absence of an acidic residue in TMS 10 to promote QacA-
mediated bivalent drug resistance. Interestingly, the incorpo-
ration of G377C/D/E/Q substitutions in wild-type QacA caused
a reduction in resistance to the majority of representative com-
pounds (Table 1), suggesting that the amino acid residue at
position 377 could be a general influence in determining the
QacA multidrug recognition profile.
To further characterize the mutant QacA transport proteins,
each was examined for its capacity to promote the efflux of
representative monovalent (ethidium) and bivalent (DAPI
[4,6-diamidino-2-phenylindole]) substrates from E. coli, as
FIG. 1. Schematic topological representation of the QacA transport protein based on results of hydropathy analysis and limited solvent
accessibility studies (11). The TMS are enclosed by gray shaded boxes and are numbered 1 to 14. The locations of D323 and L333 in TMS 10 and
G377 in TMS 12 are indicated.
TABLE 1. Relative expression and resistance capacities of QacA mutant proteins
QacA mutation Relative expression(% of wild-type QacA)c
Relative MIC of substratea,b
Monovalent Bivalent
Et (dye) R6G (dye) Bc (Qac) Dq (Qac) Pe (Dd) Ch (Bg)
Wild-type QacA 100 100 (250)d 100 (800) 100 (30) 100 (200) 100 (250) 100 (4.25)
No QacA NAe 15 45 50 15 35 10
D323C 137 200 100 100 15 40 10
D323C-G377C 83 140 90 100 40 40 10
D323C-G377D 110 200 70 100 105 65 85
D323C-G377E 109 100 55 100 70 50 60
D323C-G377Q 123 180 65 90 30 40 15
G377C 74 40 70 100 75 50 50
G377D 110 70 70 100 70 40 50
G377E 108 60 55 75 40 35 25
G377Q 111 70 55 85 45 40 35
a MICs were determined in E. coli DH5 cells expressing QacA proteins as previously described (7). Values are percentages of the MIC for strains expressing
wild-type QacA and are averages of at least two separate experiments.
b Abbreviations, Qac, quaternary ammonium compound; Dd, diamidine; Bg, biguanidine; Et, ethidium; R6G, rhodamine 6G; Bc; benzalkonium; Dq, dequalinium;
Pe, pentamidine; Ch, chlorhexidine.
c Percentage wild-type QacA expression levels are the average of five Western blot analyses.
d Values in parentheses are resistance levels conferred by wild-type QacA (g/ml).
e NA, not applicable.
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previously described (7, 11). In line with its inability to confer
resistance to bivalent cationic substrates, the D323C QacA
mutant failed to mediate the transport of DAPI above back-
ground levels (Fig. 2A). However, the D323C-G377D and
D323C-G377E QacA double mutants facilitated DAPI trans-
port at an even higher rate than the wild-type protein (Fig.
2A). In contrast, the D323C-G377C and D323C-G377Q QacA
mutants did not demonstrate significant DAPI transport activ-
ity (Fig. 2A). This implies that an acidic residue is required at
position 377 to restore the capacity for bivalent substrate rec-
ognition to the D323C QacA mutant protein. In contrast to the
reduced overall drug resistance capacity of the G377C/D/E/Q
QacA mutants (Table 1), these proteins facilitated DAPI
transport at a rate exceeding that of the wild-type protein (Fig.
2B), suggesting that these mutants may better accommodate
DAPI in the binding site. Significantly, none of the G377
amino acid substitutions made in either the wild-type or
D323C QacA backgrounds affected QacA ethidium transport
rates (Fig. 2C and D).
Previous solvent accessibility studies of the QacA transport
protein determined that amino acid positions at the C-terminal
end of TMS 10 (e.g., position 333) could be made more acces-
sible to solvent by the addition of DAPI, a finding which may
reflect conformational changes around TMS 10 that may occur
upon DAPI binding (11). To determine if an acidic residue in
TMS 10, which is pivotal for DAPI binding, is integral to the
DAPI-induced conformational switch involving TMS 10, a
D323A-L333C QacA mutant was constructed and compared to
the L333C QacA mutant for its reactivity with fluorescein
maleimide in the presence and absence of various concentra-
tions of DAPI, as previously described (11). The addition of
500 M DAPI induced an almost threefold increase in fluo-
rescein maleimide reactivity of the L333C mutant (Fig. 3A).
However, DAPI had no noteworthy effect on the level of re-
activity of the D323A-L333C mutant protein to fluorescein
maleimide (Fig. 3B). This implies that DAPI does not bind to
the D323A-L333C QacA mutant to induce a conformational
change and an associated shift in the solvent exposure of po-
sition 333. Indeed, the D323A-L333C QacA double mutant
also lacks the capacity for DAPI transport, a function main-
tained by the L333C mutant protein (data not shown). Similar
studies were conducted to determine if mutations incorporated
at position 377 would restore the capacity for a DAPI-induced
conformational shift to the D323A-L333C QacA mutant. Al-
though the DAPI transport capacities of D323A-L333C-
G377C/D/E/Q triple mutants closely reflected those of the
D323C-G377C/D/E/Q double mutants (Fig. 2A and data not
shown), the fluorescein maleimide reactivity of these QacA
triple mutants was unaffected by the addition of DAPI (data
not shown). Therefore, even though the D323A-L333C-
G377D/E QacA triple mutants were able to recognize and
transport DAPI, the dynamics of DAPI binding may be distinct
from those occurring within the L333C mutant, where DAPI
may bind in an alternative orientation.
Given that D323 of QacA is likely to partake in electrostatic
interactions with bivalent cationic substrates, the compensa-
FIG. 2. Transport mediated by mutant QacA proteins. E. coli
DH5 cells expressing G377 mutants of QacA D323C (A and C) or
wild-type QacA (B and D) were loaded with either 8 M DAPI (A and
B) or 15 M ethidium (C and D), and efflux was monitored fluoro-
metrically. The curve depicting DAPI efflux mediated by the D323C
mutant is partially obscured by the D323C-G377C QacA mutant curve
(A). Each assay was conducted in at least duplicate, and results shown
are from a representative experiment.
FIG. 3. Fluorescein maleimide reactivity studies of QacA mutant
proteins in the presence of the bivalent substrate DAPI. The L333C
(A) and D323A-L333C (B) QacA mutant proteins were reacted with
fluorescein maleimide in the presence of 0, 50, 250, and 500 M DAPI,
purified by affinity chromatography, and fractionated by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis, as previously described
(11). The fluorescence associated with each band is shown in the top
panels, and the Coomassie blue-stained QacA proteins are shown in
the lower panels. The percent reactivity to fluorescein maleimide of
the DAPI-treated samples relative to the untreated sample for each
mutant is indicated below each band.
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tory effect of incorporating an acidic residue at position 377 of
QacA after the neutralization of D323, implies that position
377 is placed within the QacA bivalent substrate binding re-
gion, where it can mediate similar interactions with substrates.
This is the first time that a residue outside TMS 10 of QacA
has been demonstrated to line the bivalent drug binding region
and reflects the remarkable flexibility in drug binding interac-
tions by QacA. Since position 377 is located away from TMS
10, it is likely to lie in a different spatial position within the
bivalent drug binding region relative to D323. Therefore, biva-
lent cationic drugs may be bound in different orientations when
stabilized by electrostatic interactions with an acidic residue at
position 377 or 323. Electrostatic interactions in the multidrug
binding site of the E. coli MdfA multidrug exporter have been
shown to be similarly flexible (1). The incorporation of an
acidic residue at position 335, which is likely to reside on a
different face of the multidrug binding site than the important
E26 (2, 5), can restore the capacity of a E26T MdfA mutant to
recognize certain cationic substrates (1).
Interestingly, despite restoring a significant overall degree of
bivalent cation resistance to the D323C QacA mutant, the level
of drug recognition restored by the G377D/E mutations varied
for different substrates and was particularly low in the case of
pentamidine. Likewise, the ability of the MdfA E26T deriva-
tive to recognize different cationic substrates after the incor-
poration of an acidic residue at position 335 varied; for some
cations no recognition was restored (1). This could be a reflec-
tion of physical constraints within the drug binding regions of
these multidrug transporters. Although there is flexibility in
the spatial organization of electrostatic interactions with some
substrates, other parts of the binding site may be more rigid
and restrict the orientation of subsets of substrates, such as
pentamidine in QacA, preventing them from readily assuming
stabilizing electrostatic interactions with acidic residues in
novel spatial positions. If this is the case, it follows that with a
reorganization of the position of important binding determi-
nants, a multidrug transporter could rapidly adapt to bind new
substrates which were previously unrecognized due to physical
constraints in mediating stabilizing binding interactions. The
observation that acidic residues exist in different positions in
the bivalent drug binding site in naturally occurring QacA/B
variants could be a manifestation of this phenomenon and
reflect specific selective forces of different environments.
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